Using Mounjaro to maintain weight: what the evidence actually says

Why weight often returns when tirzepatide stops

A misconception worth addressing clearly: some people assume that once they have lost the weight, their body will simply hold it there. It rarely works that way. The biological drivers of weight (appetite regulation, metabolic rate, hormonal signalling) do not reset to a new baseline after weight loss. Research from the SURMOUNT programme, as discussed in NICE's appraisal of tirzepatide (TA1026), showed that participants who discontinued tirzepatide after achieving significant weight loss regained a meaningful proportion of it within twelve months. Those who continued the medicine maintained most of what they had lost.

This pattern is not a failure of willpower. It reflects how appetite-regulating hormones behave after weight loss, the body mounts a biological response that pushes appetite upward. Tirzepatide counteracts that response while it is present; when it leaves the system, the counteraction goes with it. Understanding this helps frame the maintenance question honestly: continuing treatment is not a crutch, it is one legitimate clinical strategy for managing a chronic condition. For a practical guide to how to maintain weight loss after Mounjaro, including what the evidence suggests about keeping the weight off long-term, we have put together a dedicated resource worth reading alongside this page.

If you want to understand more about the timeline before that question even arises, our page on how long Mounjaro takes to work covers what to expect in the earlier stages of treatment.

What "maintaining weight on Mounjaro" looks like in practice

There is no separate licensed maintenance schedule for tirzepatide, no official switch to a lower "holding dose" built into the product licence. What maintenance looks like in practice varies: some people continue at the dose that brought them to their goal weight; others, with prescriber guidance, trial a lower dose to find the minimum effective level for them. Neither path is automatic. A prescriber reviews the clinical picture at every repeat.

The NHS patient information on tirzepatide makes clear that treatment is always under the supervision of a healthcare professional and that any changes to dosing or duration are made by your prescriber, not independently. That principle applies here too: there is no self-directed maintenance protocol, and adjusting your own dose between reviews is not recommended.

It is also worth reading about the broader picture of maintaining weight loss after Mounjaro, which covers lifestyle factors (diet quality, activity, sleep) that run alongside any medicine decision and matter regardless of which route you take.

Factors your prescriber will consider

When a prescriber at a service like nume reviews a request to continue tirzepatide for weight maintenance, they are looking at several things together. How much weight was lost and over what period? Are the weight-related conditions that supported the original prescription still present, improved or resolved? Is the current dose well-tolerated? What does the patient's own goals and circumstances look like?

They will also consider whether the medicine continues to serve a clinical purpose. If weight has been stable at goal for a sustained period and comorbidities have resolved, the risk-benefit of continuing indefinitely looks different from someone who still has active hypertension or obstructive sleep apnoea that responded to the weight loss. This is why blanket answers about maintenance duration are not helpful, the right answer is individual.

For people specifically thinking about whether there is a lower-frequency approach, our prescribers are sometimes asked about alternate-week dosing; the clinical picture on that is nuanced and worth reading before any decision.

Planning ahead: what happens if you do stop

If the clinical decision is to stop tirzepatide rather than continue, planning matters. The evidence on weight regain after stopping is clear enough that approaching it without any strategy is a risk. Our guidance on how to maintain weight loss after stopping Mounjaro is a useful resource for that conversation. The short version: the period immediately after stopping is when lifestyle foundations (consistent protein intake, regular strength activity, structured eating patterns) matter most, because the appetite suppression that made those easier to sustain will no longer be there.

There are also broader considerations about cost and duration. Treatment pricing is explained on our treatment page, and the context of how private prices have changed in the UK is covered in our article on the Eli Lilly UK price increase, worth reading if you are thinking about long-term budgeting. Maintenance as an open-ended commitment looks different financially from a time-limited treatment course, and being clear-eyed about that is part of making a good decision.

If you are thinking through any of this with an existing prescriber, our clinical team can also help. Our clinical lead's profile gives a sense of the standard of oversight involved. And if you are earlier in the journey and still deciding whether treatment is right at all, our weight-loss treatment overview is a sensible starting point.